Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Non-Current Assets (2016 - 2025)

Neurocrine Biosciences' Non-Current Assets history spans 16 years, with the latest figure at $2.1 billion for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 5.76% year-over-year to $2.1 billion; the TTM value through Dec 2025 reached $8.4 billion, up 20.77%, while the annual FY2025 figure was $2.1 billion, 5.76% up from the prior year.
  • Non-Current Assets reached $2.1 billion in Q4 2025 per NBIX's latest filing, roughly flat from $2.1 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $2.1 billion in Q2 2025 to a low of $761.0 million in Q1 2021.
  • Average Non-Current Assets over 5 years is $1.4 billion, with a median of $1.2 billion recorded in 2022.
  • Peak YoY movement for Non-Current Assets: soared 192.62% in 2021, then decreased 17.7% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $1.1 billion in 2021, then fell by 16.78% to $915.2 million in 2022, then skyrocketed by 79.68% to $1.6 billion in 2023, then grew by 21.26% to $2.0 billion in 2024, then increased by 5.76% to $2.1 billion in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Non-Current Assets are $2.1 billion (Q4 2025), $2.1 billion (Q3 2025), and $2.1 billion (Q2 2025).